UK markets open in 7 hours 21 minutes

Bayer Aktiengesellschaft (0P6S.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
56.07+0.44 (+0.80%)
At close: 05:59PM BST
Full screen
Previous close55.62
Bid55.50 x 0
Ask56.64 x 0
Day's range55.06 - 56.27
52-week range43.90 - 67.99
Avg. volume1,180,293
Market cap55.396B
Beta (5Y monthly)1.16
PE ratio (TTM)13.38
EPS (TTM)4.19
Earnings dateN/A
Forward dividend & yield2.40 (4.28%)
Ex-dividend date02 May 2023
1y target estN/A
  • Reuters

    Bayer's pharma chief hopes EU takes time to improve drug rules reform

    The European Union's decision to postpone rule changes for the pharmaceutical industry could open the way for a rethink of a decision to cut intellectual drug property protection, the head of Bayer's pharmaceuticals division said. The European Commission said this week that the publication of a first draft of a planned revision of drug legislation in the bloc would be "slightly later" than March 29, as initially planned. A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection.

  • Reuters

    Bayer plans to spend $1 billion on US pharma R&D in 2023-US pharma head

    Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, also said in an interview on Wednesday that the company had raised the number of U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years, and plans to expand on that by another 75% by 2030. "It's time for us to double down on the U.S.," Guth said, noting that Bayer plans to sell the drugs it is developing itself in the country, rather than partner with U.S. companies like it has in the past.

  • Reuters

    Explainer: Biotech corn and soy widely used, consumers still wary of GM wheat

    Nearly all corn and soybean acres in the world's largest exporting countries are seeded with genetically modified varieties, but that is not the case for wheat, a crop grown primarily for human food. Biotech varieties of corn and soy, used for animal feed, biofuels and ingredients like cooking oil, were introduced in 1996 and soon came to dominate plantings in the United States as well as Brazil and Argentina, the world's top suppliers. But genetically modified wheat has never been grown for commercial purposes due to consumer fears that allergens or toxicities could emerge in a staple used worldwide for bread, pasta and pastries.